Depletion by RNAi or specific inhibition of SOX18 homo- and heterodimerization by a small molecule inhibitor SM4 or R-propranolol [26,27] dramatically decreases both intracellular viral genome copies and release of infectious virus, suggesting SOX18 as an attractive therapeutic target for KS. This evidence concerns the gene SOX18 and Kaposi's sarcoma.